AMENDMENTS TO THE SPECIFICATION

Page 1, after the title insert the following:

This application is the US national phase of international application **PCT/EP2003/007946** filed **21 July 2003** which designated the U.S. and claims benefit of **GB 0216648.6**, dated **19 July 2002**, the entire contents of each of which are hereby incorporated by reference.

Delete the paragraph spanning line 20 of page 14 through line 13 of page 15 and insert the following therefor:

Examples of preferred, possible embodiments OF GS marker gene cassettes are given in the sequence listings. Seq IDs No. 1 (pEE 15.1 hCMV/GFP + hot spot) +2 (pEE 14.4 hCMV/GFP) give examples of suitable GS-gene cassettes that are expressed from the SV40 (early and late, respectively) promoter, a weak to medium level promoter, further comprising an expression cassette for GFP (Green fluorescent protein) that is under control of the hCMV promoter. Seq. ID No. 1 describes a GS CDNA sequence described in more detail in ~~the figure legend of~~ Fig. 3, under control of the SV40 early promoter. Seq. ID No. 2 specifies an artifical GS-minigene cassette comprising an intron that is under control of the SV40 late promoter. CHO cells are not naturally glutamine auxothropic, therefore selection schemes as e.g. described in Cockett et al. , 1990, High level expression of tissue inhibitor of metalloproteinases in Chinese Hamster Ovary (CHO) cells using Glutamine synthetase gene amplification, Bio/Technology 8: 662-667,

can be applied. Examples of suitable transfection methods for CHO cells are equally given therein ; it is possible to employ e. g. classic calcium phosphate precipitation or more modern lipofection techniques. Transfection rate is routinely defined as the number of positively transfected cells (transient transfection) or clones (stable transfection after selection period) obtained from a pool of cells subjected to transfection. The purported effect of the present object of invention can be seen e. g. by transfecting CHO-K1 cells by lipofection (any commercial reagent and manufacturers protocol) with the plasmids of either Seq. ID No. 3 (pEE 12.4 hCMV-GFP + SV40 early promoter/GS CDNA) or Seq. ID No. 4 (pEE 12.4 MCMV-GFP + SV40 early promoter/GS CDNA). Transfected cells may be grown in any conventional culture medium. The culture medium may be a fetal serum-supplemented or serum-free medium as has been defined above. Preferably, the cell culture medium is a serum-supplemented medium, more preferably a cell culture medium that has been supplemented with at least 1% (v/v) fetal serum, most preferably with at least 5% (v/v) fetal serum such as fetal calf serum or fetal bovine serum. In another preferred embodiment, the transfection method carried out is electroporation.